AUTOINMUNIDAD CONTRA LA CÉLULA BETA EN EL ADULTO MAYOR CON DIABETES TIPO 2: IMPACTO CLÍNICO, METABÓLICO Y TERAPÉUTICO

Introduction: 111 patients with diabetes with over 65 years old and non-obese (BMI <30.0 kg/m 2 ), were studied. Methods: GADA, ZnT8, IA2a and PAA, 4 antibody markers for pancreatic s cell autoimmunity were determined. Personal and familiar history of diabetes and autoimmune diseases were collected, and metabolic, biochemical, anthropometric, clinical and therapeutic variables were measured. Results: 32% of patients had at least one antibody. Most frequent antibody was PAA 58,3 %, followed by GADA 30,5%, ZnT8 27,7% and IA2A 5,5%. Patients with antibodies had greater waist, greater insulin resistance and s cell function and higher prevalence of microangiopathic complications. Insulin requirement was larger for patients with antibodies but differences were not significant. Conclusions: these results are different from those that would be expected in both Type 2 diabetes and LADA, suggesting that this population may have different features, and the issue needs further analysis. We propose the name LADE (Latent Autoimmune Diabetes in Elderly) for these patients over 65 years non-obese DM2 Au +.